Gatifloxacin-Associated Corrected QT Interval Prolongation, Torsades de Pointes, and Ventricular Fibrillation in Patients with Known Risk Factors
Open Access
- 15 March 2002
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 34 (6) , 861-863
- https://doi.org/10.1086/339075
Abstract
Drugs not commonly considered to be cardioactive agents have been reported to cause prolongation of the corrected QT interval with resultant torsadesKeywords
This publication has 9 references indexed in Scilit:
- Risk Assessment for Antimicrobial Agent‐Induced QTc Interval Prolongation and Torsades de PointesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- Gatifloxacin‐Induced QTc Prolongation and Ventricular TachycardiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- Interactions of a Series of Fluoroquinolone Antibacterial Drugs with the Human Cardiac K+Channel HERGMolecular Pharmacology, 2001
- Molecular biology of K+ channels and their role in cardiac arrhythmias11Am J Med. 2001;110-50-59.The American Journal of Medicine, 2001
- Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjectsClinical Pharmacology & Therapeutics, 2000
- QT-Prolonging Effects of Sparfloxacin, a Fluoroquinolone Antibiotic, Assessed in the In Vivo Canine Model with Monophasic Action Potential MonitoringJournal of Cardiovascular Pharmacology, 2000
- The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications Report on a Policy Conference of the European Society of CardiologyCardiovascular Research, 2000
- Quinolone-induced QT interval prolongation: a not-so-unexpected class effectJournal of Antimicrobial Chemotherapy, 2000
- QTc-interval abnormalities and psychotropic drug therapy in psychiatric patientsThe Lancet, 2000